NASDAQ: PBM
Psyence Biomedical Ltd Earnings Dates, Reports, Calls

Psyence Biomedical earnings were -$51.2M for the trailing 12 months ending Mar 31, 2024, with N/A growth year over year. The latest PBM earnings report on Mar 31, 2024 announced Q1 2024 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2024 ending Mar 31, 2024, PBM reported annual earnings of -$51.2M, with 1,495.5% growth.

PBM earnings history

Current Revenue
$0.0
Current Earnings
-$51.2M
Current Profit Margin
0%

PBM Return on Equity

Current Company
N/A
Current Industry
16.8%
Current Market
25.1%

PBM undefined

Current Company
-3,758.4%
Current Industry
3.2%
PBM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when PBM announces earnings.

PBM undefined

Current Company
465.76%
Current Industry
-42.4%

PBM vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
PBM-$51.11M-$51.16MN/A-$586.49
PTIX-$5.48M-$5.53MN/A-$1.13
ENTO-$18.01M-$18.30MN/A-$5.33
NLSP-$6.35M-$6.60MN/A-$6.74
TNFA-$23.36M-$27.16MN/A-$11.15

Psyence Biomedical Earnings Reports & History FAQ

What were Psyence Biomedical's earnings last quarter?

Psyence Biomedical (NASDAQ: PBM) reported Q1 2024 earnings per share (EPS) of N/A, up N/A year over year. Total PBM earnings for the quarter were N/A. In the same quarter last year, Psyence Biomedical's earnings per share (EPS) was -$60.69.

If you're new to stock investing, here's how to buy Psyence Biomedical stock.

Is Psyence Biomedical profitable or losing money?

As of the last Psyence Biomedical earnings report, Psyence Biomedical is currently losing money. Psyence Biomedical's net profit (also called net income) for the twelve months ending Mar 31, 2024 was -$51.16 million, a 1,495.53% increase year over year.

What was PBM's earnings growth in the past year?

As of Psyence Biomedical's earnings date in Q2 2025, Psyence Biomedical's earnings has grown year over year. PBM earnings in the past year totalled -$51.16 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.